LatestNews

OMass Therapeutics appoints Jonathan Montagu as Non-Executive Director
June 12, 2019

Oxford, 12 June 2019 – OMass Therapeutics (“OMass”), a drug discovery company using structural mass spectrometry to discover novel medicines, today…

Read More
OMass Therapeutics appoints Rosamond Deegan as Chief Executive Officer
May 8, 2019

Oxford, 8 May 2019 – OMass Therapeutics (“OMass”), a drug discovery company using structural mass spectrometry to discover novel medicines, today…

Read More
DyNAbind and OMass Therapeutics enter collaboration agreement
April 17, 2019

Dresden, Germany, 16.04.2019 – DyNAbind GmbH and OMass Therapeutics have entered a collaboration for the discovery of new fragment- and small…

Read More
OMass Therapeutics Expands its Senior Leadership Team
November 27, 2018

Dr Ali Jazayeri – Chief Scientific Officer Dr Giles Brown – VP, Medicinal Chemistry Dr Hsin Loke – VP, Head of…

Read More